AUG 19, 2015 12:52 PM PDT

Biomarkers to Diagnose Lung Cancer

Warnings about the dangers of smoking started in the 1960s, but lung cancer remains the second-most common cancer and the leading cause of death from cancer in the United States. Because patients are often diagnosed only when their disease is already at an advanced stage and hard to treat, researchers at the West Coast Metabolomics Center at UC Davis have attempted to identify biomarkers that could be the basis of early tests for lung cancer. The study was reported in Science Daily
Metabolomics catches cancer earlier. 
According to Oliver Fiehn, director of the metabolomics center and a professor of molecular and cellular biology at UC Davis, "Early diagnosis is the key to fighting lung cancer."
 
While lung cancer can be diagnosed early with regular low-dose computed tomography (CT) scans of people at risk, but they are both expensive and invasive. Fiehn, project scientist William Wikoff and their colleagues decided to look for biomarkers of developing lung cancer in blood from patients. Fiehn specializes in "metabolomics," which analyzes all of the biochemical products of metabolism in cells and tissues at the same time. The discipline, which is made possible by new technology and computing power, is opening up new ways to understand living processes.
 
The team looked at blood samples collected from people who developed the lung cancer, months or years before they were diagnosed. They were able to access samples stored from the CARET clinical trial, which ran from 1985 to 1996 and attempted to test whether doses of antioxidant vitamins could prevent cancer in heavy smokers and other people at high risk. While the trial failed, the collection of blood, serum and tissues and related data are maintained as the CARET Biorepository.
 
Using metabolomics, Wikoff and Fiehn discovered that one molecule, diacetylspermine, was almost doubled in serum collected from patients as many as six months before they were diagnosed with lung cancer, compared to healthy controls. They combined diacetylspermine with another previously identified biomarker, a protein called pro-surfactant protein B (pro-SFTPB), and tested for both markers in another set of sera collected from CARET patients months before they developed lung cancer.
 
Individually, the markers were about 70 percent predictive; in combination, they were 80 percent predictive. Thus, eight out of ten people with early-stage cancer could be correctly identified by the combined test. If this method were used, patients could then be referred for a low-dose CT scan to confirm the presence of cancer.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
OCT 16, 2019
Cancer
OCT 16, 2019
New anticancer agent discovered
A new study published in the Journal of the American Chemical Society showcases research from Purdue University on the development of an anticancer agent t...
OCT 16, 2019
Cancer
OCT 16, 2019
New Freezing Technique for Breast Cancer Patients in Low Income Countries
Treatment for breast cancer can be too expensive and hard to access for many women in lower-income countries. These women are disproportionately affected b...
OCT 16, 2019
Health & Medicine
OCT 16, 2019
Textured Breast Implants Linked to Rare Cancer Recalled
Yesterday, the U.S. Food and Drug Administration announced the recall of textured breast implants linked to breast implant-associated anaplastic large cell...
OCT 16, 2019
Drug Discovery & Development
OCT 16, 2019
Aspirin: The Good and Bad for Breast Cancer Survivors
Early research has indicated that aspirin usage may increase the survival rate among women with breast cancer. These studies were based on aspirin’s ...
OCT 16, 2019
Cancer
OCT 16, 2019
New hope for children's brain cancer DIPG
New research published in Nature Communications provides insight on a potential treatment for an aggressive form of brain cancer called Diffuse Intrinsic P...
OCT 16, 2019
Cancer
OCT 16, 2019
The role of sleeper cells in metastasis
New research published in the journal Nature Communications aims to explain why some breast cancers recur following cancer treatment. According to col...
Loading Comments...